Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

NCT02935673 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Stopped sponsor decision

Conditions

Respiratory Syncytial Viruses

Interventions

DRUG: lumicitabine
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC